Cisplatin (CIS) is a platinum based anticancer drug that has demonstrated significant efficacy against various types of cancers. Unfortunately, this drug is also famous for its severe side effects on delicate organs. Herein this study examined the hepatorenal and testicular protective effects of TiTE against CIS-induced hepatorenal and testicular insults. Rats were administered with TiTE (250 and 500 mg/kg body weight) for 4 weeks, while a single dose of CIS (2.5 mg/kg body weight) was injected

more »

... once per week from week 2 to week 4. Treatment with TITE significantly attenuated CIS-induced increases in serum creatinine, blood urea nitrogen (BUN), uric acid, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Furthermore, TiTE treatment also decreased oxidative stress (MDA) inflammations (TNF-α, IL-1β, IL-6, NF-κB) and apoptosis (caspase-3 activity) and restored hepatorenal and testicular antioxidant defense (SOD, CAT and GPx) in CIS treated rats. Additionally, the TiTE improved sperm count, motility and viability, and ameliorated the reduced serum levels of testosterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH) in CIS-injected rats. TiTE also curtailed hepatorenal and testicular histological changes in CIS treated rats. The findings from the study indicated that TiTE displayed hepatorenal and testicular protective effects via inhibition of oxidative stress-mediated inflammation and endocrine imbalance in rats.